108.31 GBP +2.95 +2.80%
Official Close 3/17/2023 BATS Europe


AstraZeneca Analyst Opinions

AstraZeneca Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 45,915 50,388 54,138 57,769 60,373
Dividend 3.05 3.16 3.31 3.43 3.69
Dividend Yield (in %) 2.34 % 2.43 % 2.54 % 2.63 % 2.83 %
EPS 7.24 8.74 9.81 10.85 11.79
P/E Ratio 18.27 15.12 13.48 12.18 11.21
EBIT 14,918 17,604 19,735 21,621 23,270
EBITDA 15,832 18,636 21,015 22,290 24,898
Net Profit 11,237 13,427 15,213 16,432 18,222
Net Profit Adjusted 11,237 13,427 15,213 16,811 18,222
Pre-Tax Profit 14,076 16,626 18,697 20,689 22,250
Net Profit (Adjusted) 8,500 11,224 13,483 15,512 17,806
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 4.70 5.88 7.12 8.02 9.47
Gross Income 37,601 41,254 44,992 48,097 50,577
Cash Flow from Investing -4,097 -3,860 -3,967 -3,876 -4,648
Cash Flow from Operations 11,652 14,022 16,255 17,465 20,852
Cash Flow from Financing -7,361 -7,827 -7,386 -7,525 -7,820
Cash Flow per Share 7.46 8.77 9.88 9.68 12.42
Free Cash Flow 8,292 10,645 12,553 12,591 15,299
Free Cash Flow per Share 5.68 6.79 8.24 9.22 -
Book Value per Share 25.40 28.64 32.86 37.63 44.80
Net Debt 20,092 14,658 7,556 3,516 -10,477
Research & Development Exp. 10,133 10,784 11,346 11,975 12,043
Capital Expenditure 1,949 1,952 2,160 2,225 2,344
Selling, General & Admin. Exp. 14,504 14,917 15,300 15,084 15,739
Shareholder’s Equity 39,219 43,776 49,123 55,682 67,362
Total Assets 95,834 98,574 103,969 108,101 119,691
  Previous Quarter
ending 12/31/22
Current Quarter
ending 03/31/23
Next Quarter
ending 06/30/23
Current Year
ending 12/31/23
Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 19 9 8 29 27
Average Estimate 1.343 USD 1.733 USD 1.723 USD 7.237 USD 8.744 USD
Year Ago 1.670 USD 1.890 USD 1.720 USD 6.660 USD 7.237 USD
Publish Date 2/9/2023 4/28/2023 7/27/2023 - -
Revenue Estimates
No. of Analysts 19 10 9 27 26
Average Estimate 11,250 USD 10,790 USD 11,046 USD 45,915 USD 50,388 USD
Year Ago 12,011 USD 11,390 USD 10,771 USD 44,351 USD 45,915 USD
Publish Date 2/9/2023 4/28/2023 7/27/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

AstraZeneca Dividend Calendar

Date Name Dividend *yield Currency
2022 AstraZeneca PLC 2.39 2.13 GBP
2021 AstraZeneca PLC 2.10 2.42 GBP
2020 AstraZeneca PLC 2.07 2.83 GBP
2019 AstraZeneca PLC 2.18 2.87 GBP
2018 AstraZeneca PLC 2.15 3.66 GBP
2017 AstraZeneca PLC 2.02 3.95 GBP
2016 AstraZeneca PLC 2.19 4.93 GBP
2015 AstraZeneca PLC 2.80 4.09 USD
2015 AstraZeneca PLC 1.89 4.08 GBP
2014 AstraZeneca PLC 1.78 3.91 GBP
2014 AstraZeneca PLC 2.80 3.95 USD
2013 AstraZeneca PLC 1.76 4.92 GBP
2013 AstraZeneca PLC 2.80 4.75 USD
2012 AstraZeneca PLC 1.79 6.14 GBP
2012 AstraZeneca PLC 2.80 6.08 USD
2011 AstraZeneca PLC 1.75 5.90 GBP
2011 AstraZeneca PLC 2.80 5.95 USD
2010 AstraZeneca PLC 2.55 5.52 USD
2010 AstraZeneca PLC 1.62 5.53 GBP
2009 AstraZeneca PLC 2.30 7.08 USD
2009 AstraZeneca PLC 1.41 4.86 GBP
2008 AstraZeneca PLC 2.05 4.77 USD
2007 AstraZeneca PLC 1.87 5.64 USD
2006 AstraZeneca PLC 1.72 4.09 USD
2005 AstraZeneca PLC 1.30 3.00 USD
2004 AstraZeneca PLC 0.94 3.25 USD
2003 AstraZeneca PLC 0.80 1.95 USD
2002 AstraZeneca PLC 0.70 2.06 USD
2001 AstraZeneca PLC 0.70 1.48 USD
2000 AstraZeneca PLC 0.70 1.35 USD
1999 AstraZeneca PLC 0.70 1.82 USD
*Yield of the Respective Date

AstraZeneca PLC Calendar

Event Estimate Info Date
Annual General Meeting - Annual General Meeting 04/27/2023
Earnings Report 1.733 USD Q1 2023 Earnings Release 04/28/2023
Earnings Report 1.723 USD Q2 2023 Earnings Release 07/27/2023
Earnings Report - Q3 2023 Earnings Release 11/09/2023
Earnings Report - Q4 2023 Earnings Release 02/08/2024

AstraZeneca PLC Past Events

Event Actual EPS Info Date
Earnings Report 1.380 USD Q4 2022 Earnings Release 02/09/2023
Shareholders' Meeting - - 04/29/2022

AstraZeneca Profile

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

AstraZeneca Shareholder

Owner in %
Freefloat 94.95
Government Pension Fund - Global (The) 2.32
Vanguard Health Care Fund 1.28
Vanguard Total International Stock Index Fund 1.26
American Funds EuroPacific Growth Fund 0.78
Goldman Sachs GQG Partners International Opportunities Fund 0.78
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

AstraZeneca Management

Name Job
Jeffrey Pott CHRO, Chief Compliance Officer & General Counsel
Michel Demaré Chairman-Designate
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability
Cindy L. Hoots Chief Digital & Information Officer
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Strategy Officer
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Tyrell J. Rivers Executive Director-Corporate Development
Ruud Dobber Executive VP-Biopharmaceuticals Business
Susan Mary Galbraith Executive VP-Oncology Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Iskra Reic Executive Vice President-Europe & Canada
David Fredrickson Executive Vice President-Oncology Business Unit
Jonathan Thomas Charles Slade Group Treasurer
Kevin G. Lokay Head-U.S. Immuno-oncology
Nazneen Rahman Independent Non-Executive Director
Marcus Wallenberg Independent Non-Executive Director
Tony Mok Independent Non-Executive Director
Sherilyn D. McCoy Independent Non-Executive Director
Deborah DiSanzo Independent Non-Executive Director
Ahmed M. Hamdy Member
Leif Valdemar Johansson Non-Executive Chairman
Diana Layfield Non-Executive Director
Andreas Rummelt Non-Executive Director
Euan A. Ashley Non-Executive Director
Regina Fritsche Danielson SVP, Head-Research & Early Development
Adrian Charles Noel Kemp Secretary
Sarah Miksinski Senior Director-Global Regulatory Affairs
Philip Arthur John Broadley Senior Independent Non-Executive Director
Margareta Elisabeth Björk Senior VP & Head-Late-stage Development
Helen MacPhee Vice President
Sjoerd Hubben Vice President-Global Government Affairs & Policy